Fundraising Fox

Nurocor

Austin, US · Delaware corporation · 1 known investors

Nurocor offers an AI-native clinical platform that converts clinical trial protocols from static documents into structured, machine-readable digital assets, automating study design, standards governance (CDISC, ICH M11, USDM), specimen management, and document authoring. It serves pharmaceutical companies aiming to reduce cost and time in clinical development.

AI & Machine LearningDigital HealthSaaS

Founders & leadership

GM
Gregg MartinExecutive
ALAlex Lazar
Alex LazarinFounder, Board Member, President, and CEO
PGPaul Gigg
Paul GigginChairman/Founder
GMGreg Martin
Greg MartinNamed on SEC filing

Investors · 1

Recurring Capital PartnersAustin

Reported raises · per SEC filings

Form D private placements

$6.6M disclosed across 6 of 7 rounds · 2022–2025

▶$460KraisedMay 2025 · 8 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gregg MartinExecutive Officer, Director
  • Paul GiggExecutive Officer, Director
  • Alex LazarExecutive Officer, Director
Offering amount
$3M
Amount sold
$460K
First sale
Apr 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedApr 2025 · 1 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul GiggExecutive Officer, Director
  • Gregg MartinExecutive Officer, Director
  • Alex LazarExecutive Officer, Director
Offering amount
$500K
Amount sold
$500K
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$125KraisedFeb 2025 · 1 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alex LazarExecutive Officer, Director
  • Paul GiggExecutive Officer, Director
  • Gregg MartinExecutive Officer, Director
Offering amount
$125K
Amount sold
$125K
First sale
Jan 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$250KraisedFeb 2025 · 1 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul GiggExecutive Officer, Director
  • Alex LazarExecutive Officer, Director
  • Greg MartinExecutive Officer, Director
Offering amount
$250K
Amount sold
$250K
First sale
Oct 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedOct 2024 · 27 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gregg MartinExecutive Officer, Director
  • Alex LazarExecutive Officer, Director
  • Paul GiggExecutive Officer, Director
Offering amount
$7.5M
Amount sold
$5M
First sale
Sep 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$350KraisedOct 2024 · 1 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul GiggExecutive Officer, Director
  • Gregg MartinExecutive Officer, Director
  • Alex LazarExecutive Officer, Director
Offering amount
$350K
Amount sold
$350K
First sale
Sep 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedJun 2022 · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul GiggExecutive Officer
  • Alex LazarExecutive Officer
  • Greg MartinExecutive Officer
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
NovoCure7 shared keywordsNovocure develops Tumor Treating Fields therapy for treating aggressive forms of cancer. The company focuses on patient-centered innovation in oncology.

Companies competing with Nurocor for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Nurocor Receives $1M Investment from Simulations Plusfinsmes.com · Jul 2025Simulations Plus Invests in Clinical Development Technology Company Nurocor - Simulations Plussimulations-plus.com · Jul 2025About Us – Nurocornurocor.com · Dec 2021About Us - 2022 – Nurocorncr.brandwithintent.com · Dec 2021

Frequently asked questions

What does Nurocor do?
Nurocor offers an AI-native clinical platform that converts clinical trial protocols from static documents into structured, machine-readable digital assets, automating study design, standards governance (CDISC, ICH M11, USDM), specimen management, and document authoring. It serves pharmaceutical companies aiming to reduce cost and time in clinical development.
Who are Nurocor's investors?
Nurocor's investors include Recurring Capital Partners.
How much funding has Nurocor raised?
Nurocor has disclosed $6.6M raised across 6 of its 7 known rounds.
Where is Nurocor headquartered?
Nurocor is headquartered in Austin, US.